Combination of Enfortumab Vedotin and Pembrolizumab Has Radically Improved Bladder Cancer Treatment

Based on ongoing data from the EV-302 trial—Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer—the Danish Medicines Council recommended on December 18, 2024, the use of enfortumab vedotin in combination with pembrolizumab as first-line treatment for adult patients with inoperable or metastatic urothelial carcinoma who are eligible for platinum-based chemotherapy.